Cefepime versus ceftazidime in the treatment of lower respiratory tract infections.
Author(s): Aufiero A, Sturani C, Zanon P, Marruchella A, Michetti G, Nicolin E, Sella D, Goglio A, Silleni M, La Regina A
Affiliation(s): Divisione di Pneumologia, Ospedale E.Morelli, Sondalo, Italy.
Publication date & source: 1997-06, J Chemother., 9(3):213-8.
Publication type: Clinical Trial; Clinical Trial, Phase III; Randomized Controlled Trial
The objective of the study was to compare the safety and efficacy of cefepime and ceftazidime in the treatment of community acquired lower respiratory tract infections of moderate intensity. Eighty-six patients were randomized at a 2:1 ratio to receive respectively cefepime 1 g b.i.d. or ceftazidime 1 g t.i.d. The drugs were well tolerated and the occurrence of adverse events in each group was comparable. The rates of satisfactory clinical response were 96% (49/51) for cefepime and 89% (24/27) for ceftazidime. A total of 73 pathogens were isolated and pathogen eradication rates were 98% and 96% respectively for the cefepime and ceftazidime treatment groups. In conclusion, the data confirmed that cefepime could be a good alternative to ceftazidime.